Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today ...
This statement is issued on behalf of the Bonderman family, TPG, Wildcat Capital Management and the Seattle Kraken. It is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback